Pacira Pharms Inc patents expiration
1. Depocyt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5455044 | PACIRA PHARMS INC | Method for treating neurological disorders |
May, 2013
(10 years ago) | |
| US5723147 | PACIRA PHARMS INC | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
Mar, 2015
(9 years ago) | |
Drugs and Companies using CYTARABINE ingredient
Market Authorisation Date: 01 April, 1999
Treatment: Intrathecal treatment of lymphomatous meningitis
Dosage: INJECTABLE, LIPOSOMAL;INJECTION
DEPOCYT family patents
2. Depodur patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5723147 | PACIRA PHARMS INC | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
Mar, 2015
(9 years ago) | |
| US5931809 | PACIRA PHARMS INC | Epidural administration of therapeutic compounds with sustained rate of release |
Jul, 2015
(8 years ago) | |
| US5807572 | PACIRA PHARMS INC | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
Sep, 2015
(8 years ago) | |
| US6241999 | PACIRA PHARMS INC | Method for producing liposomes with increased percent of compound encapsulated |
Sep, 2016
(7 years ago) | |
| US6193998 | PACIRA PHARMS INC | Method for producing liposomes with increased percent of compound encapsulated |
Sep, 2016
(7 years ago) | |
| US5997899 | PACIRA PHARMS INC | Method for producing liposomes with increased percent of compound encapsulated |
Sep, 2016
(7 years ago) | |
| US6171613 | PACIRA PHARMS INC | Method for producing liposomes with increased percent of compound encapsulated |
Oct, 2016
(7 years ago) | |
| US5891467 | PACIRA PHARMS INC | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
Jan, 2017
(7 years ago) | |
| US5962016 | PACIRA PHARMS INC | Multivesicular liposomes utilizing neutral lipids to modify in vivo release |
Jan, 2017
(7 years ago) | |
Drugs and Companies using MORPHINE SULFATE ingredient
Market Authorisation Date: 18 May, 2004
Treatment: Single-dose administration by the epidural route, at the lumbar level, for the treatment of pain following major surgery
Dosage: INJECTABLE, LIPOSOMAL;EPIDURAL
DEPODUR family patents
3. Exparel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6132766 | PACIRA PHARMS INC | Multivesicular liposomes with controlled release of encapsulated biologically active substances |
Nov, 2013
(10 years ago) | |
| US8834921 | PACIRA PHARMS INC | Sustained-release liposomal anesthetic compositions |
Sep, 2018
(5 years ago) | |
| US8182835 | PACIRA PHARMS INC | Sustained-release liposomal anesthetic compositions |
Sep, 2018
(5 years ago) | |
| US9205052 | PACIRA PHARMS INC | Sustained-release liposomal anesthetic compositions |
Sep, 2018
(5 years ago) | |
| US9585838 | PACIRA PHARMS INC | Production of multivesicular liposomes |
Dec, 2021
(2 years ago) | |
| US11278494 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11357727 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11304904 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11819574 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11452691 | PACIRA PHARMS INC | Compositions of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11179336 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11426348 | PACIRA PHARMS INC | Compositions of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11819575 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11033495 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11311486 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 22, 2024 |
| New Indication(I-929) | Nov 09, 2026 |
| New Indication(I-771) | Apr 06, 2021 |
| New Product(NP) | Oct 28, 2014 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 28 October, 2011
Treatment: Single-dose infiltration into the surgical site to produce postsurgical analgesia.; Single dose administration into the surgical site to produce postsurgical analgesia; Method of treating pain, for ex...
Dosage: INJECTABLE, LIPOSOMAL;INJECTION
EXPAREL family patents
4. Zilretta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8828440 | PACIRA PHARMS INC | Corticosteroids for the treatment of joint pain |
Aug, 2031
(7 years from now) | |
| US9555048 | PACIRA PHARMS INC | Corticosteroids for the treatment of joint pain |
Aug, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 06, 2020 |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 06 October, 2017
Treatment: Method of treating pain or inflammation with an injectable controlled or sustained release formulation of triamcinolone acetonide
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR
ZILRETTA family patents